MetLife Investment Management’s Compass Therapeutics CMPX Stock Holding History

MetLife Investment Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Sell	64,205 -9,780	-13%	-$56.5K	﹤0.01%	1945
2025 Q4	$397K	Buy	73,985 +15,638	+27%	+$72.2K	﹤0.01%	1900
2025 Q3	$204K	Sell	58,347 -599	-1%	-$1.89K	﹤0.01%	2305
2025 Q2	$153K	Buy	58,946 +21,779	+59%	+$44.9K	﹤0.01%	2326
2025 Q1	$70.6K	Sell	37,167 -25,974	-41%	-$69.1K	﹤0.01%	2645
2024 Q4	$91.6K	Buy	63,141 +42,115	+200%	+$69.9K	﹤0.01%	2657
2024 Q3	$38.7K	Sell	21,026 -3,351	-14%	-$4.18K	﹤0.01%	2781
2024 Q2	$24.4K	Sell	24,377 -26,153	-52%	-$38.2K	﹤0.01%	2861
2024 Q1	$100K	Buy	50,530 +577	+1%	+$997	﹤0.01%	2538
2023 Q4	$77.9K	Hold	49,953	–	–	﹤0.01%	2702
2023 Q3	$98.4K	Hold	49,953	–	–	﹤0.01%	2587
2023 Q2	$159K	Buy	+49,953	New	+$157K	﹤0.01%	2408

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's CMPX Position: Q1 2026 in Review

MetLife Investment Management reduced its Compass Therapeutics (CMPX) stake by 13% in Q1 2026, selling an estimated $56.5K and leaving 64,205 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

MetLife Investment Management first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. The position peaked at $397K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

MetLife Investment Management held 64,205 shares of Compass Therapeutics worth $340K as of Q1 2026.
MetLife Investment Management sold 9,780 Compass Therapeutics shares in Q1 2026, an estimated $56.5K.
Compass Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1945 holding.
MetLife Investment Management first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
MetLife Investment Management's Compass Therapeutics position peaked at $397K in Q4 2025.
201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.